Ovid Therapeutics Inc. Research and Development Expense
Ovid Therapeutics Inc. (OVID) reported Research and Development Expense of $9.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Ovid Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $9.96M, a 54.01% increase year-over-year.
- Ovid Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $11.18M, a 67.91% increase year-over-year.
- Ovid Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $6.59M, a 11.24% increase year-over-year.
- Ovid Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $5.87M, a 25.27% decline year-over-year.
- Ovid Therapeutics Inc. research and development expense for fiscal 2025 was $25.58M, a 30.42% decline from fiscal 2024.
- Ovid Therapeutics Inc. research and development expense for fiscal 2024 was $36.77M, a 28.61% increase from fiscal 2023.
- Ovid Therapeutics Inc. research and development expense for fiscal 2023 was $28.59M, a 16.12% increase from fiscal 2022.
- Ovid Therapeutics Inc. research and development expense for fiscal 2022 was $24.62M, a 47.55% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.96M 10-Q · filed 2026-08-13 | $21.14M 10-Q · filed 2026-08-13 | $27.73M derived: sum of 3 quarters · filed 2026-08-13 | $33.60M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $11.18M 10-Q · filed 2026-05-12 | $17.77M derived: sum of 2 quarters · filed 2026-05-12 | $23.64M derived: sum of 3 quarters · filed 2026-05-12 | $30.11M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $6.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $12.46M derived: sum of 2 quarters · filed 2026-03-18 | $18.92M derived: sum of 3 quarters · filed 2026-08-13 | $25.58M 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | $5.87M 10-Q · filed 2025-11-12 | $12.34M derived: sum of 2 quarters · filed 2026-08-13 | $18.99M 10-Q · filed 2025-11-12 | $24.92M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $6.46M 10-Q · filed 2026-08-13 | $13.12M 10-Q · filed 2026-08-13 | $19.05M derived: sum of 3 quarters · filed 2026-08-13 | $26.90M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $6.66M 10-Q · filed 2026-05-12 | $12.58M derived: sum of 2 quarters · filed 2026-05-12 | $20.44M derived: sum of 3 quarters · filed 2026-05-12 | $33.02M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $13.78M derived: sum of 2 quarters · filed 2026-03-18 | $26.36M derived: sum of 3 quarters · filed 2026-03-18 | $36.77M 10-K · filed 2026-03-18 | ||||
| 2024-09-30 | $7.86M 10-Q · filed 2025-11-12 | $20.44M derived: sum of 2 quarters · filed 2025-11-12 | $30.84M 10-Q · filed 2025-11-12 | $41.48M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $12.58M 10-Q · filed 2025-08-13 | $22.98M 10-Q · filed 2025-08-13 | $33.62M derived: sum of 3 quarters · filed 2025-08-13 | $38.95M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $10.40M 10-Q · filed 2025-05-13 | $21.04M derived: sum of 2 quarters · filed 2025-05-13 | $26.37M derived: sum of 3 quarters · filed 2025-05-13 | $32.37M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $10.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $15.97M derived: sum of 2 quarters · filed 2025-03-11 | $21.97M derived: sum of 3 quarters · filed 2025-03-11 | $28.59M 10-K · filed 2025-03-11 | $28.59M 10-K · filed 2024-03-08 | |||
| 2023-09-30 | $5.33M 10-Q · filed 2024-11-12 | $5.33M 10-Q · filed 2023-11-03 | $11.33M derived: sum of 2 quarters · filed 2024-11-12 | $17.95M 10-Q · filed 2024-11-12 | $17.95M 10-Q · filed 2023-11-03 | $23.50M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $6.00M 10-Q · filed 2024-08-13 | $6.00M 10-Q · filed 2023-08-04 | $12.61M 10-Q · filed 2024-08-13 | $12.61M 10-Q · filed 2023-08-04 | $18.17M derived: sum of 3 quarters · filed 2024-08-13 | $23.35M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $6.62M 10-Q · filed 2024-05-14 | $6.61M 10-Q · filed 2023-05-05 | $12.17M derived: sum of 2 quarters · filed 2024-05-14 | $17.35M derived: sum of 3 quarters · filed 2024-05-14 | $23.40M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $5.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $10.74M derived: sum of 2 quarters · filed 2024-03-08 | $16.79M derived: sum of 3 quarters · filed 2024-03-08 | $24.62M 10-K · filed 2024-03-08 | ||||
| 2022-09-30 | $5.18M 10-Q · filed 2023-11-03 | $11.23M derived: sum of 2 quarters · filed 2023-11-03 | $19.06M 10-Q · filed 2023-11-03 | $37.15M derived: sum of 4 quarters · filed 2023-11-03 | ||||
| 2022-06-30 | $6.05M 10-Q · filed 2023-08-04 | $13.88M 10-Q · filed 2023-08-04 | $31.97M derived: sum of 3 quarters · filed 2023-08-04 | $36.89M derived: sum of 4 quarters · filed 2023-08-04 | ||||
| 2022-03-31 | $7.83M 10-Q · filed 2023-05-05 | $25.92M derived: sum of 2 quarters · filed 2023-05-05 | $30.84M derived: sum of 3 quarters · filed 2023-05-05 | $38.52M derived: sum of 4 quarters · filed 2023-05-05 | ||||
| 2021-12-31 | $18.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $23.01M derived: sum of 2 quarters · filed 2023-03-13 | $30.69M derived: sum of 3 quarters · filed 2023-03-13 | $46.94M 10-K · filed 2023-03-13 | ||||
| 2021-09-30 | $4.92M 10-Q · filed 2022-11-08 | $12.60M derived: sum of 2 quarters · filed 2022-11-08 | $28.85M 10-Q · filed 2022-11-08 | $45.73M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $7.68M 10-Q · filed 2022-08-09 | $23.93M 10-Q · filed 2022-08-09 | $40.82M derived: sum of 3 quarters · filed 2022-08-09 | $56.69M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $16.25M 10-Q · filed 2022-05-10 | $33.13M derived: sum of 2 quarters · filed 2022-05-10 | $49.01M derived: sum of 3 quarters · filed 2022-05-10 | $65.04M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $16.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $32.76M derived: sum of 2 quarters · filed 2022-03-15 | $48.79M derived: sum of 3 quarters · filed 2022-03-15 | $63.42M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $15.88M 10-Q · filed 2021-11-10 | $31.91M derived: sum of 2 quarters · filed 2021-11-10 | $46.53M 10-Q · filed 2021-11-10 | $58.64M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $16.03M 10-Q · filed 2021-08-16 | $30.66M 10-Q · filed 2021-08-16 | $42.76M derived: sum of 3 quarters · filed 2021-08-16 | $54.36M derived: sum of 4 quarters · filed 2021-08-16 | ||||
| 2020-03-31 | $14.63M 10-Q · filed 2021-05-13 | $26.73M derived: sum of 2 quarters · filed 2021-05-13 | $38.33M derived: sum of 3 quarters · filed 2021-05-13 | $47.45M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $12.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $23.70M derived: sum of 2 quarters · filed 2021-03-15 | $32.82M derived: sum of 3 quarters · filed 2021-03-15 | $42.16M 10-K · filed 2021-03-15 | ||||
| 2019-09-30 | $11.60M 10-Q · filed 2020-11-13 | $20.72M derived: sum of 2 quarters · filed 2020-11-13 | $30.05M 10-Q · filed 2020-11-13 | $38.67M derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2019-06-30 | $9.12M 10-Q · filed 2020-08-10 | $18.45M 10-Q · filed 2020-08-10 | $27.08M derived: sum of 3 quarters · filed 2020-08-10 | $35.62M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $9.34M 10-Q · filed 2020-05-07 | $17.96M derived: sum of 2 quarters · filed 2020-05-07 | $26.50M derived: sum of 3 quarters · filed 2020-05-07 | $34.62M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $8.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $17.17M derived: sum of 2 quarters · filed 2020-03-11 | $25.28M derived: sum of 3 quarters · filed 2020-03-11 | $33.79M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $8.54M 10-Q · filed 2019-11-08 | $16.66M derived: sum of 2 quarters · filed 2019-11-08 | $25.17M 10-Q · filed 2019-11-08 | $31.85M derived: sum of 4 quarters · filed 2019-11-08 | ||||
| 2018-06-30 | $8.12M 10-Q · filed 2019-08-07 | $16.59M 10-Q · filed 2019-08-07 | $23.30M derived: sum of 3 quarters · filed 2019-08-07 | $29.20M derived: sum of 4 quarters · filed 2019-08-07 | ||||
| 2018-03-31 | $8.47M 10-Q · filed 2019-05-07 | $15.19M derived: sum of 2 quarters · filed 2019-05-07 | $21.09M derived: sum of 3 quarters · filed 2019-05-07 | $27.16M derived: sum of 4 quarters · filed 2019-05-07 | ||||
| 2017-12-31 | $6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $12.61M derived: sum of 2 quarters · filed 2019-03-07 | $18.69M derived: sum of 3 quarters · filed 2019-03-07 | $49.97M 10-K · filed 2019-03-07 | ||||
| 2017-09-30 | $5.90M 10-Q · filed 2018-11-08 | $11.97M derived: sum of 2 quarters · filed 2018-11-08 | $43.26M 10-Q · filed 2018-11-08 | $47.25M derived: sum of 4 quarters · filed 2018-11-08 | ||||
| 2017-06-30 | $6.07M 10-Q · filed 2018-08-09 | $37.36M 10-Q · filed 2018-08-09 | $41.35M derived: sum of 3 quarters · filed 2018-08-09 | $44.05M derived: sum of 4 quarters · filed 2018-08-09 | ||||
| 2017-03-31 | $31.28M 10-Q · filed 2018-05-08 | $35.28M derived: sum of 2 quarters · filed 2018-05-08 | $37.97M derived: sum of 3 quarters · filed 2018-05-08 | $39.74M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2016-12-31 | $3.99M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $6.69M derived: sum of 2 quarters · filed 2018-03-29 | $8.46M derived: sum of 3 quarters · filed 2018-03-29 | $9.59M 10-K · filed 2018-03-29 | ||||
| 2016-09-30 | $2.70M 10-Q · filed 2017-11-09 | $4.47M derived: sum of 2 quarters · filed 2017-11-09 | $5.59M 10-Q · filed 2017-11-09 | |||||
| 2016-06-30 | $1.77M 10-Q · filed 2017-08-10 | $2.90M 10-Q · filed 2017-08-10 | ||||||
| 2016-03-31 | $1.13M 10-Q · filed 2017-06-13 | |||||||
| 2015-12-31 | $6.61M 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |